基于真实世界数据的皮肌炎患者特征、治疗与结局
本研究利用美国两个全国代表性队列(商业理赔与ENRICH电子健康记录)描述初发皮肌炎患者的特征、治疗与结局。共识别理赔队列2475例、EHR队列1196例;糖皮质激素使用普遍(68.7%与73.8%),初始剂量多>20 mg/日,理赔队列平均累积剂量1407 mg;羟氯喹、甲氨蝶呤和霉酚酸酯为最常用免疫调节治疗。理赔队列随访期间全因住院、恶性肿瘤、间质性肺病、胃造瘘管置入和心肌炎发生率分别为每1000人年92.2、15.3、6.4、2.9和2.1。
要点
- 初发皮肌炎患者糖皮质激素暴露负担高,初始剂量多>20 mg/日。
- 羟氯喹、甲氨蝶呤和霉酚酸酯是最常用的免疫调节治疗。
- 理赔队列全因住院发生率为每1000人年92.2,医疗利用度高。
核心结论
- 理赔与EHR数据可用于评估初发皮肌炎的治疗模式和纵向结局。
- 该人群糖皮质激素暴露负担高、治疗异质性显著且医疗利用度高。
研究设计与样本
- 回顾性描述性流行病学研究,使用两个美国全国代表性初发皮肌炎队列:商业理赔数据与ENRICH电子健康记录数据。
- 理赔队列评估诊断前18个月至诊断后12个月,EHR队列评估诊断前12个月至诊断后12个月。
主要发现
- 识别理赔队列2475例、EHR队列1196例初发皮肌炎患者。
- EHR队列998例有实验室数据者中472例有肌炎panel结果,165例(35.0%)肌炎特异性抗体阳性。
- 糖皮质激素使用率在理赔与EHR队列分别为68.7%与73.8%,初始剂量多>20 mg/日。
- 理赔队列糖皮质激素使用者平均累积剂量为1407 mg。
- 理赔队列随访期间每1000人年发生率:全因住院92.2、恶性肿瘤15.3、间质性肺病6.4、胃造瘘管置入2.9、心肌炎2.1。
临床怎么用
- 真实世界数据可用于监测初发皮肌炎的治疗模式、糖皮质激素累积暴露及纵向结局。
- 临床应关注该人群的高糖皮质激素负担、治疗异质性及高住院风险。
局限性
- 研究为回顾性设计,基于理赔与EHR数据,可能存在编码或记录不完整。
- 肌炎panel结果仅在EHR队列部分患者中可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Studies of dermatomyositis (DM) are frequently limited to single-centre cohorts. We used two large nationally representative US cohorts to conduct a descriptive epidemiological study of the characteristics, treatments and outcomes of patients with incident DM. METHODS: This retrospective study identified two DM inception cohorts using (1) commercial claims and (2) electronic health record (EHR) data from the Excellence Network in Rheumatology to Innovate Care and High-impact research (ENRICH), a community rheumatology practice-based research network. Patient characteristics, treatments and healthcare utilisation were assessed using the 18 months before and 12 months after diagnosis in claims and the 12 months before and after diagnosis in EHR data. RESULTS: We identified 2475 patients (claims) and 1196 patients (EHR) with incident DM. Among 998 patients in the EHR cohort with available laboratory data, 472 had available myositis panel results, with 165 (35.0%) having a positive myositis-specific antibody. Glucocorticoid use was common, 68.7% and 73.8% in the two cohorts, respectively, with initial doses most often >20 mg/day; among glucocorticoid users, mean cumulative dose was 1407 mg in the claims cohort. Hydroxychloroquine, methotrexate and mycophenolate were the most commonly used immunomodulatory therapies. During follow-up in the claims data cohort, incidence per 1000 person-years was 92.2, 15.3, 6.4, 2.9 and 2.1 for all-cause hospitalisation, malignancy, interstitial lung disease, gastrostomy tube placement and myocarditis, respectively. CONCLUSION: Administrative claims and EHR data can be leveraged to assess treatment patterns and longitudinal outcomes/disease manifestations in incident dermatomyositis cohorts. This study highlights a high burden of glucocorticoid exposure, significant heterogeneity in treatment and high healthcare utilisation in this population.
引用
- George M, Romich E, Riley TR, et al. Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data. RMD Open. 2026. PMID: 41592913. doi:10.1136/rmdopen-2025-006356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。